

SUPPLEMENTARY MATERIALS

Fear of missing out: Drug availability in the United States vs Canada

Short title: Drug availability in the United States vs Canada

Mina Tadrous, PharmD, PhD; Clara Chen, BHSc; Katherine Callaway Kim, MPH; Martin Ho, PharmD; Joel Lexchin, MD; Inmaculada Hernandez, PharmD, PhD; Katie J. Suda, PharmD, MS

SUPPLEMENTARY TABLE 1 Additional Therapeutic Value of Drugs in the “Not Available Without Alternatives Marketed” Category

Supplemental Appendix

Additional Methods description:

First, we considered drugs available in the US (or individual APIs, for combination products without matches in the DPD) that were listed in the DPD but not marketed. Among those drugs, we identified products listed as “cancelled post-market” or as “dormant; approved but not marketed; cancelled pre-market.” Second, we considered drugs with alternative formulations of the US API that were marketed in Canada. We categorized these as “same API but different formulation.” Third, we considered drugs with APIs not listed in the DPD and categorized them into five classes: 1) “existing drug class,” if there was at least one drug with the same mechanism of action marketed in Canada; 2) “therapeutically similar,” if there was a drug in another class with similar effectiveness and safety marketed in Canada; 3) “pre-notice of compliance,” if there was a submission for the drug pending regulatory review, as listed on Health Canada’s Drug and Health Product Submissions Under Review database; 4) “atypical access available,” if available through special access programs from manufacturers or government agencies; and 5) “unavailable without alternatives marketed.”⁶ The availability of drugs with comparable effectiveness and safety was determined through a search of available literature and product labeling. Similar effectiveness and safety in humans according to the literature was reviewed by two authors (CC and MH), with disagreements reconciled by a third author (MT).

Table 1: Additional therapeutic value of drugs in the “not available without alternatives marketed” category

Drug (n=9)	Prescrire International	Haute Autorité de Santé	Institute for Quality and Efficiency in Health Care (IQWiG)
Bezlotoxumab	Minor to none	Minor to none	Non-quantifiable benefit
Crizanlizumab	Minor to none	Minor to none	Minor to none
Fenoldopam			

Omacetaxine mepesuccinate			
Pramlintide			
Tagraxofusp		Minor to none	Non-quantifiable benefit
Talimogene laherparpvec			Minor to none
Vestronidase alfa		Minor to none	
Ziconotide	Minor to none		

REFERENCES

1. Indicators O. Health at a Glance 2023. 2023;
2. Morgan S, Lopert R, Greyson D. Toward a definition of pharmaceutical innovation. *Open Med.* 2008;2(1):e4-7.
3. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* Apr 2008;61(4):344-9. doi:10.1016/j.jclinepi.2007.11.008
4. Rosshandler Y, Shen AQ, Cortes J, Khoury HJ. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia. *Expert Rev Hematol.* May 2016;9(5):419-24. doi:10.1586/17474086.2016.1151351
5. Avgerinos I, Manolopoulos A, Michailidis T, et al. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis. *Diabetes Obes Metab.* Mar 2021;23(3):822-831. doi:10.1111/dom.14291